Reference health
Net Reclassification Improvement: Computation, Interpretation, and Controversies
124/124 checkable references clean · checked 2026-07-24
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
4 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 124 checked references that resolve
resolves10.7326/0003-4819-55-1-33
Factors of Risk in the Development of Coronary Heart Disease—Six-Year Follow-up Experience
resolves10.1001/jama.285.19.2486
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
resolves10.1093/eurheartj/ehs092
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
resolves10.1093/eurheartj/ehr236
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
resolves10.1200/JCO.2008.20.5179
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction
resolves10.1182/blood-2010-10-300970
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
resolves10.1111/j.1445-5994.2010.02339.x
Use of risk stratification to guide ambulatory management of neutropenic fever
resolves10.1093/aje/kwh101
Limitations of the Odds Ratio in Gauging the Performance of a Diagnostic, Prognostic, or Screening Marker
resolves10.1161/CIRCULATIONAHA.106.672402
Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction
resolves10.1002/sim.5598
Predictive accuracy of risk factors and markers: a simulation study of the effect of novel markers on different performance measures for logistic regression models
resolves10.1161/CIRCULATIONAHA.109.192278
Criteria for Evaluation of Novel Markers of Cardiovascular Risk
resolves10.7326/0003-4819-145-1-200607040-00128
The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women
resolves10.1002/sim.2929
Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond
resolves10.1093/ije/dyr013
Use of reclassification for assessment of improved prediction: an empirical evaluation
resolves10.3310/hta5080
Issues in methodological research: perspectives from researchers and commissioners
resolves10.1515/CCLM.2010.340
Statistical methods for assessment of added usefulness of new biomarkers
resolves10.1002/sim.4085
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers
resolves10.1002/sim.4348
Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models
resolves10.7326/0003-4819-150-11-200906020-00007
Advances in Measuring the Effect of Individual Predictors of Cardiovascular Risk: The Role of Reclassification Measures
resolves10.1001/jama.2012.434
Association of Major and Minor ECG Abnormalities With Coronary Heart Disease Events
resolves10.7326/0003-4819-151-7-200910060-00009
C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force
resolves10.7326/0003-4819-155-6-201109200-00006
Screening Asymptomatic Adults With Resting or Exercise Electrocardiography: A Review of the Evidence for the U.S. Preventive Services Task Force
resolves10.7326/0003-4819-150-8-200904210-00008
Joint Effects of Common Genetic Variants on the Risk for Type 2 Diabetes in U.S. Men and Women of European Ancestry
resolves10.7326/0003-4819-156-9-201205010-00004
Serum 25-Hydroxyvitamin D Concentration and Risk for Major Clinical Disease Events in a Community-Based Population of Older Adults
resolves10.1001/jama.2010.1768
Association of Troponin T Detected With a Highly Sensitive Assay and Cardiac Structure and Mortality Risk in the General Population
resolves10.1001/jama.2010.1708
Association of Serial Measures of Cardiac Troponin T Using a Sensitive Assay With Incident Heart Failure and Cardiovascular Mortality in Older Adults
resolves10.1001/jama.2012.9630
Common Carotid Intima-Media Thickness Measurements in Cardiovascular Risk Prediction
resolves10.1001/jama.2012.5502
Association Between Postoperative Troponin Levels and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery
resolves10.7326/0003-4819-154-9-201105030-00008
Individualized Guidelines: The Potential for Increasing Quality and Reducing Costs
resolves10.1016/S0140-6736(13)60108-7
Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II
resolves10.1001/jama.2012.7870
Comparison of 30-Day Mortality Models for Profiling Hospital Performance in Acute Ischemic Stroke With vs Without Adjustment for Stroke Severity
resolves10.1001/jama.2013.1363
Association of Fibrosis With Mortality and Sudden Cardiac Death in Patients With Nonischemic Dilated Cardiomyopathy
resolves10.7326/0003-4819-151-7-200910060-00010
Emerging Risk Factors for Coronary Heart Disease: A Summary of Systematic Reviews Conducted for the U.S. Preventive Services Task Force
resolves10.7326/0003-4819-149-10-200811180-00009
Assessing the Value of Risk Predictions by Using Risk Stratification Tables
resolves10.7326/0003-4819-154-6-201103150-00008
Strengthening the Reporting of Genetic Risk Prediction Studies: The GRIPS Statement
resolves10.1016/S0140-6736(09)61717-7
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis
resolves10.1056/NEJMoa0706728
Polymorphisms Associated with Cholesterol and Risk of Cardiovascular Events
resolves10.7326/0003-4819-156-6-201203200-00006
Evaluation of Newer Risk Markers for Coronary Heart Disease Risk Classification
resolves10.1001/jama.2011.1896
Serial Changes in Highly Sensitive Troponin I Assay and Early Diagnosis of Myocardial Infarction
resolves10.1056/NEJMoa1001689
Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
resolves10.1056/NEJMoa0801209
Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List
resolves10.7326/0003-4819-154-7-201104050-00003
Using Additional Information on Working Hours to Predict Coronary Heart Disease
resolves10.7326/0003-4819-157-6-201209180-00002
Development and Validation of a Coronary Risk Prediction Model for Older U.S. and European Persons in the Cardiovascular Health Study and the Rotterdam Study
resolves10.1001/jama.2010.1690
Association Between Familial Atrial Fibrillation and Risk of New-Onset Atrial Fibrillation
resolves10.1056/NEJMoa0801869
Clinical Risk Factors, DNA Variants, and the Development of Type 2 Diabetes
resolves10.7326/0003-4819-157-12-201212180-00005
One-Year Risk for Advanced Colorectal Neoplasia: U.S. Versus U.K. Risk-Stratification Guidelines
resolves10.1001/jama.2012.3954
Comparison of Risk Prediction Using the CKD-EPI Equation and the MDRD Study Equation for Estimated Glomerular Filtration Rate
resolves10.1056/NEJMoa0804742
Genotype Score in Addition to Common Risk Factors for Prediction of Type 2 Diabetes
resolves10.1001/jama.2009.943
Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community
resolves10.7326/0003-4819-150-2-200901200-00003
Cardiovascular Disease Risk Prediction With and Without Knowledge of Genetic Variation at Chromosome 9p21.3
resolves10.1001/jama.2010.119
Association Between a Literature-Based Genetic Risk Score and Cardiovascular Events in Women
resolves10.1001/jama.2011.468
Detection of Chronic Kidney Disease With Creatinine, Cystatin C, and Urine Albumin-to-Creatinine Ratio and Association With Progression to End-Stage Renal Disease and Mortality
resolves10.1001/jama.2010.461
Coronary Artery Calcium Score and Risk Classification for Coronary Heart Disease Prediction
resolves10.1016/S0140-6736(10)61267-6
A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses
resolves10.7326/0003-4819-153-7-201010050-00005
Multicenter Validation of the Diagnostic Accuracy of a Blood-Based Gene Expression Test for Assessing Obstructive Coronary Artery Disease in Nondiabetic Patients
resolves10.1001/2012.jama.11089
Prevalence and Prognosis of Unrecognized Myocardial Infarction Determined by Cardiac Magnetic Resonance in Older Adults
resolves10.1016/S0140-6736(09)60443-8
Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study
resolves10.1056/NEJMoa0908359
Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults
resolves10.7326/0003-4819-152-3-201002020-00019
Reclassification Calculations for Persons With Incomplete Follow-up
resolves10.1001/jama.2011.451
A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure
resolves10.1001/jama.2009.1757
Assessment of Claims of Improved Prediction Beyond the Framingham Risk Score
resolves10.1016/S0140-6736(11)60105-0
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies
resolves10.1016/S0140-6736(11)61122-7
Body-mass index, abdominal adiposity, and cardiovascular risk – Authors' reply
resolves10.1001/jama.2012.9624
Comparison of Novel Risk Markers for Improvement in Cardiovascular Risk Assessment in Intermediate-Risk Individuals
resolves10.1056/NEJMoa0707064
Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes
resolves10.1161/CIR.0b013e31820faaf8
Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update
resolves10.1093/biostatistics/kxr001
Comparing costs associated with risk stratification rules for t-year survival
resolves10.1007/s10654-012-9759-6
Net reclassification improvement: a link between statistics and clinical practice
resolves10.1093/aje/kwr013
Problems With Risk Reclassification Methods for Evaluating Prediction Models
resolves10.1093/aje/kwq122
Improvement of Risk Prediction by Genomic Profiling: Reclassification Measures Versus the Area Under the Receiver Operating Characteristic Curve
resolves10.1007/s10654-012-9744-0
Assessing improvement in disease prediction using net reclassification improvement: impact of risk cut-offs and number of risk categories
resolves10.1093/ije/dyr083
Commentary: Reporting standards are needed for evaluations of risk reclassification
resolves10.1001/archinte.168.21.2304
Assessing New Biomarkers and Predictive Models for Use in Clinical Practice
resolves10.1002/sim.2995
The need for reorientation toward cost‐effective prediction: Comments on ‘Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond’ by M. J. Pencina <i>et al</i>., <i>Statistics in Medicine</i> (DOI: 10.1002/sim.2929)
resolves10.1002/bimj.201000078
Performance of reclassification statistics in comparing risk prediction models
resolves10.1161/circ.106.25.3143
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report
resolves10.1161/CIRCULATIONAHA.111.075929
Comparison of the Framingham and Reynolds Risk Scores for Global Cardiovascular Risk Prediction in the Multiethnic Women's Health Initiative
resolves10.1007/s10654-013-9824-9
Risk categorization for calculating net reclassification improvement
resolves10.1093/aje/kwr374
Risk Prediction Measures for Case-Cohort and Nested Case-Control Designs: An Application to Cardiovascular Disease
resolves10.1373/clinchem.2012.186007
Biases Introduced by Choosing Controls to Match Risk Factors of Cases in Biomarker Research
resolves10.1002/sim.3106
Comments on ‘Integrated discrimination and net reclassification improvements—Practical advice’
resolves10.1002/sim.2991
Comments on ‘Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond’ by M. J. Pencina <i>et al</i>., <i>Statistics in Medicine</i> (DOI: 10.1002/sim.2929)
resolves10.1136/bmj.327.7426.1267
Predictive accuracy of the Framingham coronary risk score in British men:prospective cohort study
resolves10.1016/S0195-668X(03)00081-2
Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts
resolves10.1016/j.ahj.2007.03.022
Validity of the Framingham point scores in the elderly: Results from the Rotterdam study
resolves10.1177/1741826711410256
Risk prediction of incident coronary heart disease in the Netherlands: re-estimation and improvement of the SCORE risk function
resolves10.1136/bmj.e3318
Comparisons of established risk prediction models for cardiovascular disease: systematic review
resolves10.1097/01.CCM.0000275267.64078.B0
Assessing the calibration of mortality benchmarks in critical care: The Hosmer-Lemeshow test revisited*
resolves10.1002/sim.4209
Comments on ‘Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers’ by M. J. Pencina, R. B. D'Agostino, Sr. and E. W. Steyerberg
resolves10.1093/aje/kwq223
External Validity of Risk Models: Use of Benchmark Values to Disentangle a Case-Mix Effect From Incorrect Coefficients
resolves10.1002/sim.2987
Comments on ‘Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond’ by M. J. Pencina <i>et al</i>., <i>Statistics in Medicine</i> (DOI: 10.1002/sim.2929)
resolves10.1177/0272989X12461856
A Bias-Corrected Net Reclassification Improvement for Clinical Subgroups
resolves10.7326/0003-4819-157-4-201208210-00014
Beyond the Usual Prediction Accuracy Metrics: Reporting Results for Clinical Decision Making
resolves10.1177/0272989X06295361
Decision Curve Analysis: A Novel Method for Evaluating Prediction Models
resolves10.1186/1471-2288-11-13
One statistical test is sufficient for assessing new predictive markers
resolves10.1016/j.amjcard.2008.02.094
Risk Prediction of Coronary Heart Disease Based on Retinal Vascular Caliber (from the Atherosclerosis Risk In Communities [ARIC] Study)
The 4 references without a DOI — listed, not checked
no DOI — not checkedr35-8
no DOI — not checkedr63-8
no DOI — not checkedr89-8
no DOI — not checkedr110-8
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-24 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.7326/m13-1522"><img src="https://citestamp.com/citestamped/10.7326/m13-1522/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.7326/m13-1522)